top of page

Nuvalent's CEO on overcoming kinase resistance and selectivity for its precision oncology medicines

Jim Porter describes the chemistry that has led to early stage success against ALK and ROS1, and he previews a HER2 program that is scheduled to enter the clinic soon.



Comentários


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page